First study to combine an anti-ICOS antibody with an anti-PD-L1 antibody in Phase I/II studies will evaluate Kymab's lead investigational therapy KY1044 with atezolizumab (TECENTRIQ®) in multiple solid tumours in a trial expected to start in 2019
Kymab announces today its clinical trial agreement with F. Hoffmann-La Roche Ltd under which Roche will provide its PD-L1 blocking antibody atezolizumab for use in combination with Kymab's lead investigational anti-ICOS antibody therapy KY1044 in Kymab's upcoming Phase I/II clinical studies in patients with advanced solid cancers.
"We have presented preclinical data demonstrating strong synergies between an anti-PD-L1 treatment in combination with KY1044 against multiple tumour types," says Arndt Schottelius, MD, PhD, Executive Vice President, Research and Development of Kymab. "We look forward to the initiation of our first studies and exploration of the potential synergy of our programs for the benefit of patients with advanced solid cancers."
Kymab will be responsible for conducting the clinical trials, and both companies will share data from the trials. Kymab continues to retain all commercial rights to KY1044.
KY1044 is designed to both deplete intratumoral Regulatory T-cells and stimulate T Effector cells to enhance the immune response against tumors.
Kymab plans to conduct a Phase I/II study in a variety of solid tumours both as monotherapy and in combination with atezolizumab. Indications that have elevated levels of both ICOS and FOXP3 might be especially responsive to this combination of checkpoint inhibitors.
Kymab will lead studies to evaluate this hypothesis: atezolizumab, an anti-PD-L1 antibody that acts as a checkpoint inhibitor, and KY1044, an antibody targeting ICOS expression, will be tested for synergistic action to recalibrate the immune response. Kymab plans to initiate monotherapy studies of KY1044 in the first half of 2019 and studies in combination with TECENTRIQ in the second half.
Notes to Editors
Issued Cambridge, UK, 28 June 2018
Read the PDF version of the issued Press Release
TECENTRIQ (atezolizumab) is a registered trademark of Genentech, a member of the Roche Group.
KY1044 is a fully human monoclonal antibody discovered by Kymab’s unique suite of technologies. KY1044 has now been tested in number of highly illustrative syngeneic models, which demonstrate that KY1044 strongly inhibits tumor growth in cancers both as a monotherapy and in combination with other immunotherapies.
Inducible T Cell Co Stimulator (ICOS), is expressed upon activation on T cells and at high levels on the majority of FOXP3+ regulatory CD4+ T cells. Importantly, available data demonstrate that depletion of these immunosuppressive cells from the tumor microenvironment enhances the patient’s anti-tumor immune response.
Kymab is an emerging clinical-stage biopharmaceutical company focused on the discovery and development of fully human monoclonal antibody drugs using its proprietary antibody platform which contains a full diversity of human antibodies, making it the most comprehensive antibody development platform available.
Kymab’s platform has been designed to maximize the diversity of human antibodies produced in response to immunization with antigens. Selecting from a broad diversity of fully human antibodies assures the highest probability of finding drug candidates with best-in-class characteristics quickly and efficiently. Kymab is leveraging its platform for its internal drug discovery programs and in partnership with pharmaceutical companies.
For more information please see http://www.kymab.com.
Kymab is a trademark of Kymab Limited.
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of our control, that could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning our plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. We undertake no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
Dan Budwick, 1AB
Consilium Strategic Communications
Mary-Jane Elliott / Jessica Hodgson / Sukaina Virji
Tel: +44 (0) 20 3709 5700
Brandon Lewis, +44 (0)1223 833301